Insulet (PODD) has disclosed a new risk, in the Natural and Human Disruptions category.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Insulet faces significant business and financial risks from the potential emergence of another global pandemic or new variants of COVID-19. Such events could disrupt clinical trials and delay FDA product approvals, as seen with Omnipod 5 during the COVID-19 pandemic. A shift to remote work has heightened cybersecurity threats, posing risks to IT systems and data integrity. Furthermore, pandemics could severely impact Insulet’s supply chain, affecting manufacturing, distribution, and third-party services critical to product sterilization and delivery.
The average PODD stock price target is $321.50, implying 13.68% upside potential.
To learn more about Insulet’s risk factors, click here.